These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940 [TBL] [Abstract][Full Text] [Related]
3. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172 [TBL] [Abstract][Full Text] [Related]
4. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
5. Associations between quantitative [ Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512 [TBL] [Abstract][Full Text] [Related]
6. Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [ Young CB; Landau SM; Harrison TM; Poston KL; Mormino EC; Neuroimage; 2021 Nov; 243():118553. PubMed ID: 34487825 [TBL] [Abstract][Full Text] [Related]
7. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675 [TBL] [Abstract][Full Text] [Related]
9. Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET. Hong J; Kang SK; Alberts I; Lu J; Sznitman R; Lee JS; Rominger A; Choi H; Shi K; Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3061-3072. PubMed ID: 35226120 [TBL] [Abstract][Full Text] [Related]
10. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372 [TBL] [Abstract][Full Text] [Related]
12. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052 [TBL] [Abstract][Full Text] [Related]
13. Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Chen SD; Lu JY; Li HQ; Yang YX; Jiang JH; Cui M; Zuo CT; Tan L; Dong Q; Yu JT; Transl Psychiatry; 2021 Sep; 11(1):483. PubMed ID: 34537810 [TBL] [Abstract][Full Text] [Related]